Evidence map›Paper›PMID 40059108›Full record

ArticleLung2025

Predictors of Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry.

Hyun J Kim, Jeremy M Weber, Megan L Neely, Amy Hajari Case, Aiham H Jbeli, Peide Li, Amy L Olson, Laurie D Snyder, IPF-PRO Registry investigators

Abstract read
In one paragraph

Article in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Murine models of pulmonary fibrosis: mechanisms, limitations and translational insights.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hyun J KimUniversity of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. kimxx015@umn.edu.ORCID 0000-0001-7986-7798
Jeremy M WeberDuke Clinical Research Institute, Durham, NC, USA.
Megan L NeelyDuke Clinical Research Institute, Durham, NC, USA.ORCID 0000-0002-0101-1081
Amy Hajari CasePiedmont Healthcare, Atlanta, GA, USA.
Aiham H JbeliUniversity of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA.
Peide LiBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Amy L OlsonBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.ORCID 0000-0002-5368-0412
Laurie D SnyderDuke Clinical Research Institute, Durham, NC, USA.ORCID 0000-0002-5962-2184
IPF-PRO Registry investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe used data from the IPF-PRO Registry of patients with idiopathic pulmonary fibrosis (IPF) to identify characteristics that predicted survival for a further > 5 years.

methodsParticipants had IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Patients were followed prospectively. A Classification And Regression Tree (CART) was used to identify predictors of survival > 5 versus ≤ 5 years following enrollment. The following variables, assessed at enrollment, were considered: age; body mass index (BMI); former smoker; current smoker; time from first imaging evidence, symptoms, or diagnosis of IPF to enrollment; forced vital capacity (FVC) % predicted; diffusing capacity of the lungs for carbon monoxide (DLco) % predicted; antifibrotic drug use; supplemental oxygen use; history of cardiac disease; pulmonary hypertension; COPD/emphysema; and rural location.

resultsThe analysis cohort comprised 819 patients, of whom 278 (33.9%) survived > 5 years. DLco % predicted, supplemental oxygen use and FVC % predicted were the most important variables for predicting survival > 5 versus ≤ 5 years after enrollment. The importance of these variables (scaled such that the most important had an importance of 100%) was 100%, 78.2% and 74.2%, respectively. The optimism-corrected area under the curve (AUC) of the CART was 0.72, with an accuracy of 0.72.

conclusionAmong patients enrolled in the IPF-PRO Registry, a decision tree that included DLco % predicted, oxygen use and FVC % predicted facilitated the prediction of survival > 5 years. Understanding predictors of longer-term survival may facilitate conversations with patients about their prognosis and treatment.

Indexed as

Idiopathic Pulmonary FibrosisAgedAge FactorsAntifibrotic AgentsBody Mass IndexFemaleHumansMaleMiddle AgedOxygen Inhalation TherapyPrognosisProspective StudiesPulmonary Diffusing CapacityRegistriesRisk FactorsSmokingAntifibrotic AgentsInterstitial lung diseasesMortalityObservational studyPrognosis

Identifiers

PMID40059108
PMCPMC11891094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.